|
1
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hirsch FR, Scagliotti GV, Mulshine JL,
Kwon R, Curran WJ Jr, Wu YL and Paz-Ares L: Lung cancer: Current
therapies and new targeted treatments. Lancet. 389:299–311. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tanino R, Tsubata Y, Harashima N, Harada M
and Isobe T: Novel drug-resistance mechanisms of pemetrexed-treated
non-small cell lung cancer. Oncotarget. 9:16807–16821. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tian S, Quan H, Xie C, Guo H, Lü F, Xu Y,
Li J and Lou L: YN968D1 is a novel and selective inhibitor of
vascular endothelial growth factor receptor-2 tyrosine kinase with
potent activity in vitro and in vivo. Cancer Sci. 102:1374–1380.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Li J, Zhao X, Chen L, Guo H, Lv F, Jia K,
Yv K, Wang F, Li C, Qian J, et al: Safety and pharmacokinetics of
novel selective vascular endothelial growth factor receptor-2
inhibitor YN968D1 in patients with advanced malignancies. BMC
Cancer. 10:5292010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Maroufi NF, Rashidi MR, Vahedian V,
Akbarzadeh M, Fattahi A and Nouri M: Therapeutic potentials of
apatinib in cancer treatment: Possible mechanisms and clinical
relevance. Life Sci. 241:1171062020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wu F, Zhang S, Gao G, Zhao J, Ren S and
Zhou C: Successful treatment using apatinib with or without
docetaxel in heavily pretreated advanced non-squamous non-small
cell lung cancer: A case report and literature review. Cancer Biol
Ther. 19:141–144. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Duan JC, Wang ZJ, Lin L, Li JL, Wang Y,
Bai H, Hu XS, Liu YT, Hao XZ, Wang HY, et al: Apatinib, a novel
VEGFR inhibitor plus docetaxel in advanced lung adenocarcinoma
patients with wild-type EGFR: A phase I trial. Invest New Drugs.
37:731–737. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jiang Q, Zhang NL, Ma DY, Tan BX, Hu X and
Fang XD: Efficacy and safety of apatinib plus docetaxel as the
second or above line treatment in advanced nonsquamous NSCLC: A
multi center prospective study. Medicine (Baltimore).
98:e160652019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mi YJ, Liang YJ, Huang HB, Zhao HY, Wu CP,
Wang F, Tao LY, Zhang CZ, Dai CL, Tiwari AK, et al: Apatinib
(YN968D1) reverses multidrug resistance by inhibiting the efflux
function of multiple ATP-binding cassette transporters. Cancer Res.
70:7981–7991. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li J, Jia Y, Gao Y, Chang Z, Han H, Yan J
and Qin Y: Clinical efficacy and survival analysis of apatinib
combined with docetaxel in advanced esophageal cancer. Onco Targets
Ther. 12:2577–2583. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li YJ, Lei YH, Yao N, Wang CR, Hu N, Ye
WC, Zhang DM and Chen ZS: Autophagy and multidrug resistance in
cancer. Chin J Cancer. 36:522017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Azam F, Latif MF, Farooq A, Tirmazy SH,
AlShahrani S, Bashir S and Bukhari N: Performance status assessment
by using ECOG (Eastern Cooperative Oncology Group) score for cancer
patients by oncology healthcare professionals. Case Rep Oncol.
12:728–736. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lencioni R and Llovet JM: Modified RECIST
(mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis.
30:52–60. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Feng H, Cheng X, Kuang J, Chen L, Yuen S,
Shi M, Liang J, Shen B, Jin Z, Yan J and Qiu W: Apatinib-induced
protective autophagy and apoptosis through the AKT-mTOR pathway in
anaplastic thyroid cancer. Cell Death Dis. 9:10302018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lu W, Ke H, Qianshan D, Zhen W, Guoan X
and Honggang Y: Apatinib has anti-tumor effects and induces
autophagy in colon cancer cells. Iran J Basic Med Sci. 20:990–995.
2017.PubMed/NCBI
|
|
17
|
Liu K, Ren T, Huang Y, Sun K, Bao X, Wang
S, Zheng B and Guo W: Apatinib promotes autophagy and apoptosis
through VEGFR2/STAT3/BCL-2 signaling in osteosarcoma. Cell Death
Dis. 8:e30152017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fu H, Jin C, Zhu Q, Liu T, Ke B, Li A and
Zhang T: Dysregulated expressions of PTEN, NF-kB, WWP2, p53 and
c-Myc in different subtypes of B cell lymphoma and reactive
follicular hyperplasia. Am J Transl Res. 11:1092–1101.
2019.PubMed/NCBI
|
|
19
|
Feng SQ, Wang GJ, Zhang JW, Xie Y, Sun RB,
Fei F, Huang JQ, Wang Y, Aa JY and Zhou F: Combined treatment with
apatinib and docetaxel in A549 ×enograft mice and its cellular
pharmacokinetic basis. Acta Pharmacol Sin. 39:1670–1680. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liang L, Hui K, Hu C, Wen Y, Yang S, Zhu
P, Wang L, Xia Y, Qiao Y, Sun W, et al: Autophagy inhibition
potentiates the anti-angiogenic property of multikinase inhibitor
anlotinib through JAK2/STAT3/VEGFA signaling in non-small cell lung
cancer cells. J Exp Clin Cancer Res. 38:712019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bulatov E, Sayarova R, Mingaleeva R,
Miftakhova R, Gomzikova M, Ignatyev Y, Petukhov A, Davidovich P,
Rizvanov A and Barlev NA: Isatin-schiff base-copper (II) complex
induces cell death in p53-positive tumors. Cell Death Discov.
4:1032018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Petrylak DP, de Wit R, Chi KN, Drakaki A,
Sternberg CN, Nishiyama H, Castellano D, Hussain SA, Fléchon A,
Bamias A, et al: Ramucirumab plus docetaxel versus placebo plus
docetaxel in patients with locally advanced or metastatic
urothelial carcinoma after platinum-based therapy (RANGE): Overall
survival and updated results of a randomised, double-blind, phase 3
trial. Lancet Oncol. 21:105–120. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Takahari D: Second-line chemotherapy for
patients with advanced gastric cancer. Gastric Cancer. 20:395–406.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Garon EB, Ciuleanu TE, Arrieta O, Prabhash
K, Syrigos KN, Goksel T, Park K, Gorbunova V, Kowalyszyn RD, Pikiel
J, et al: Ramucirumab plus docetaxel versus placebo plus docetaxel
for second-line treatment of stage IV non-small-cell lung cancer
after disease progression on platinum-based therapy (REVEL): A
multicentre, double-blind, randomised phase 3 trial. Lancet.
384:665–673. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen ZJ, Le HB, Zhang YK, Qian LY, Sekhar
KR and Li WD: Lung resistance protein and multidrug resistance
protein in non-small cell lung cancer and their clinical
significance. J Int Med Res. 39:1693–1700. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Pan B, Chen D, Huang J, Wang R, Feng B,
Song H and Chen L: HMGB1-mediated autophagy promotes docetaxel
resistance in human lung adenocarcinoma. Mol Cancer. 13:1652014.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chen T, Ren H, Thakur A, Yang T, Li Y,
Zhang S, Wang T and Chen MW: Decreased level of klotho contributes
to drug resistance in lung cancer cells: Involving in
klotho-mediated cell autophagy. DNA Cell Biol. 35:751–757. 2016.
View Article : Google Scholar : PubMed/NCBI
|
